Medtronic’s Valiant Navion(TM) Thoracic Stent Graft System Receives FDA Approval for Aortic Diseases

 Medtronic’s Valiant Navion(TM) Thoracic Stent Graft System Receives FDA Approval for Aortic Diseases

Medtronic Reports Results of Symplicity Renal Denervation System in Two Studies for Hypertensive Heart Diseases

Shots:

  • The approval is based on 1EP analysis of 87 subjects involved in IDE study enrolling 37.9% female & 71.3% patients with systemic diseases, testing its safety and efficacy in TAA and PAU patients
  • Results: Acc. To FreeFlo, CoveredSeal configuration: no instances of access or deployment failures (74.7%, 25.3%); mean procedure and fluoroscopy times (88.7 ± 53.4/12.2 ± 8.8 mins); low rates of peri-operative mortality 2.3% & secondary procedures at 2.3%; Type Ia endoleaks 1.2%
  • Valiant Navion structure is based on Valiant Captivia system with improved performance, having CoveredSeal & FreeFlo configurations offering two graft options for patients with TAA, BTAI, PAU, IMH, TBAD

Click here to read full press release/ article | Ref: Medtronic | Image: Compelo

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post